|
Patent landscape, scope, and claims: |
United States Patent 5,234,957: Scope, Claims, and US Patent Landscape
What does US Patent 5,234,957 cover?
US Patent 5,234,957 is a granted US drug patent (issue date Aug. 10, 1993). The public record identifies it as a US patent in the drug space, but the full, line-by-line claim set and the complete specification context required for a scoped infringement and validity map are not available in the provided material.
What are the independent claims, and what is the claim structure?
A complete scope analysis requires the exact independent claim wording (claim numbers, limitations, preamble, Markush structure, ranges, and functional language), plus dependent-claim dependencies. That content is not included in the information available in this session, so a correct claim chart cannot be produced.
How broad is the scope: composition, method, or use?
A scope assessment for a drug patent depends on whether the asserted subject matter is:
- Composition of matter (API, salts, polymorphs, hydrates, stereochemistry, solvates)
- Method of manufacture
- Methods of treatment / use claims (indications, dosing regimens, patient selection)
- Intermediates and process claims tied to a specific synthetic route
Those categories can only be assigned accurately by reading the actual claim text, which is not present here.
What does the US claims language likely require (claim construction axes)?
A proper construction requires the literal terms in the independent claims, including:
- Chemical definition form (chemical name vs Markush group)
- Parameters (molecular weight, purity, particle size, ClogP, stability)
- Therapeutic endpoints (disease state, biomarker)
- Administration specifics (route, dosing interval, mg range)
- Functional limitations (e.g., “effective amount,” “substantially free of,” “stable at”)
Without the claim text, any construction would be non-verifiable.
What is the US patent landscape around 5,234,957?
Landscape analysis requires at least:
- Same-family US applications/grants
- Citation network (backward citations and forward citations)
- Related continuation/divisional filings
- Active FTO-relevant patents (including design-arounds)
- Terminal disclaimers, patent term adjustments, and ownership changes
No citation graph, family set, or forward/backward references are provided here, so the landscape cannot be built accurately.
What are the key FTO drivers for this patent?
To identify FTO drivers, the analysis must map:
- Claim scope vs commercially relevant products (formulations, salts, polymorphs)
- Around-the-edges design options (different salt, different polymorph, different dosing regimen)
- Likely invalidity pressure points (prior art structures, obviousness combinations, enablement, written description)
- Litigation or licensing signals (if any)
Those require specific patent claim content and a prior-art record that is not available here.
How does this patent affect generic entry risk in the US?
Generic entry risk depends on whether 5,234,957 is:
- Listed in Orange Book for a specific NDA/ANDA
- Still within enforceable term after any disclaimers/adjustments
- Triggering paragraph IV ANDA strategy (for composition and method patents)
- Superseded by later formulation or use patents
No Orange Book listing data, NDA linkage, or enforceable-term calculations are included.
Key Takeaways
- A complete and accurate scope and claims analysis for US Patent 5,234,957 requires the actual claim text and specification context; it is not available in the provided inputs.
- A defensible US patent landscape build (family, citation network, forward-looking FTO set, Orange Book linkage, and term status) cannot be produced from the information available in this session.
- No verifiable, claim-by-claim infringement or validity mapping is possible without the missing record.
FAQs
1) What are the independent claims of US 5,234,957?
Independent claim wording is required for accuracy; it is not present in the provided material.
2) Is US 5,234,957 a composition-of-matter or method patent?
That categorization depends on the claim text; it is not available in the provided material.
3) What is the patent family for US 5,234,957?
Family members require bibliographic and legal-document data; none is provided here.
4) Which Orange Book products list US 5,234,957?
Orange Book listing data and NDA/ANDA associations are not included in the provided material.
5) What patents are most relevant for FTO around 5,234,957?
A forward/backward citation analysis and competitive portfolio mapping are required; none is provided here.
References
[1] United States Patent 5,234,957. (Bibliographic identification only as provided in the request).
More… ↓
⤷ Start Trial
|
